ATE411801T1 - Verwendung von oxindol-derivaten bei der behandlung von demenzbedingten krankheiten, alzheimer-krankheit und erkrankungen im zusammenhang mit glykogen-synthase-kinase-3 - Google Patents

Verwendung von oxindol-derivaten bei der behandlung von demenzbedingten krankheiten, alzheimer-krankheit und erkrankungen im zusammenhang mit glykogen-synthase-kinase-3

Info

Publication number: ATE411801T1
Authority: AT; Austria
Prior art keywords: diseases; dementia; alzheimer; disease; treatment
Prior art date: 2001-12-21

Application number

AT02793675T

Other languages

English (en)

Inventor

Stefan Berg

Ratan Bhat

Philip Edwards

Sven Hellberg

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-21

Filing date

2002-12-18

Publication date

2008-11-15

2002-12-18 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-11-15 Application granted granted Critical

2008-11-15 Publication of ATE411801T1 publication Critical patent/ATE411801T1/de

Links

208000024827 Alzheimer disease Diseases 0.000 title 2
206010012289 Dementia Diseases 0.000 title 1
102000001267 GSK3 Human genes 0.000 title 1
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
150000005623 oxindoles Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT02793675T 2001-12-21 2002-12-18 Verwendung von oxindol-derivaten bei der behandlung von demenzbedingten krankheiten, alzheimer-krankheit und erkrankungen im zusammenhang mit glykogen-synthase-kinase-3 ATE411801T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US34488701P	2001-12-21	2001-12-21

Publications (1)

Publication Number	Publication Date
ATE411801T1 true ATE411801T1 (de)	2008-11-15

Family

ID=23352491

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02793675T ATE411801T1 (de)	2001-12-21	2002-12-18	Verwendung von oxindol-derivaten bei der behandlung von demenzbedingten krankheiten, alzheimer-krankheit und erkrankungen im zusammenhang mit glykogen-synthase-kinase-3

Country Status (11)

Country	Link
US (2)	US20050070559A1 (de)
EP (1)	EP1458394B1 (de)
JP (2)	JP4393196B2 (de)
AR (1)	AR037881A1 (de)
AT (1)	ATE411801T1 (de)
AU (1)	AU2002359161A1 (de)
DE (1)	DE60229554D1 (de)
ES (1)	ES2314123T3 (de)
TW (1)	TW200301123A (de)
UY (1)	UY27592A1 (de)
WO (1)	WO2003055492A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1458711B1 (de)	2001-12-21	2007-07-18	AstraZeneca AB	Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
SE0302546D0 (sv)	2003-09-24	2003-09-24	Astrazeneca Ab	New compounds
SE0200979D0 (sv) *	2002-03-28	2002-03-28	Astrazeneca Ab	New compounds
US7576074B2 (en)	2002-07-15	2009-08-18	Rice Kenneth D	Receptor-type kinase modulators and methods of use
EP2210607B1 (de)	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs
GT200500321A (es)	2004-11-09	2006-09-04		Compuestos y composiciones como inhibidores de proteina kinase.
UY29198A1 (es) *	2004-11-09	2006-05-31	Cancer Rec Tech Ltd	Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
EP2258358A3 (de)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
EP2275095A3 (de)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP1940389A2 (de)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation von neurogenese durch pde-hemmung
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
US20070287707A1 (en) *	2006-02-28	2007-12-13	Arrington Mark P	Phosphodiesterase 10 inhibitors
US20090099175A1 (en) *	2006-03-01	2009-04-16	Arrington Mark P	Phosphodiesterase 10 inhibitors
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
WO2007120102A1 (en) *	2006-04-19	2007-10-25	Astrazeneca Ab	New substituted oxindole derivatives
EP2382975A3 (de)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenese mittels Angiotensin-Modulation
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
CN101573352A (zh)	2006-10-21	2009-11-04	艾博特股份有限两合公司	杂环化合物和其作为糖原合酶激酶3抑制剂的用途
US20090291982A1 (en) *	2008-05-22	2009-11-26	Astrazeneca Ab	New Substituted Oxindole Derivative 352
NZ779754A (en)	2009-01-16	2023-04-28	Exelixis Inc	Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
TW201040191A (en)	2009-03-27	2010-11-16	Abbott Gmbh & Co Kg	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
MX336726B (es)	2010-09-27	2016-01-27	Abbott Gmbh & Co Kg	Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
US9090592B2 (en)	2010-12-30	2015-07-28	AbbVie Deutschland GmbH & Co. KG	Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP3741375A1 (de)	2014-07-17	2020-11-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verfahren zur behandlung von erkrankungen in zusammenhang mit neuromuskulären verbindungen
WO2016207366A1 (en)	2015-06-26	2016-12-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en)	2015-11-05	2015-12-23	King S College London	Combination
WO2019100062A1 (en)	2017-11-20	2019-05-23	Ichan School Of Medicine At Mount Sinai	Kinase inhibitor compounds and compositions and methods of use
WO2019136320A1 (en)	2018-01-05	2019-07-11	Icahn School Of Medicine At Mount Sinai	Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
CN112135613A (zh)	2018-03-20	2020-12-25	西奈山伊坎医学院	激酶抑制剂化合物和组合物及使用方法
JP2022515650A (ja) *	2018-12-31	2022-02-21	アイカーンスクールオブメディシンアットマウントサイナイ	キナーゼ阻害剤化合物及び組成物ならびに使用方法
JP7416842B2 (ja) *	2022-02-18	2024-01-17	ナショナルヘルスリサーチインスティテューツ	縮合多環式化合物の調製方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5686624A (en) *	1992-01-30	1997-11-11	Sanofi	1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) *	1992-01-30	1997-09-02	Sanofi	1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
TW530047B (en) *	1994-06-08	2003-05-01	Pfizer	Corticotropin releasing factor antagonists
GB9707800D0 (en) *	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
ES2289791T3 (es) *	1997-08-22	2008-02-01	Astrazeneca Ab	Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
CA2340701C (en) *	1998-08-20	2009-05-26	Sumitomo Pharmaceuticals Co., Ltd.	Oxindole derivatives as growth hormone releasers
EP1136493A1 (de) *	2000-03-23	2001-09-26	Sanofi-Synthelabo	2-(Thienopyridinyl)pyrimidon-, 2-(Furopyridinyl)pyrimidon-2-(isoquinolinyl)pyrimidon-, 2-(Pyridoindolyl)pyrimidon- und 2-(Benzofuropyridinyl)pyrimidonderivate

2002
- 2002-12-13 TW TW091136112A patent/TW200301123A/zh unknown
- 2002-12-17 AR ARP020104912A patent/AR037881A1/es unknown
- 2002-12-18 ES ES02793675T patent/ES2314123T3/es not_active Expired - Lifetime
- 2002-12-18 JP JP2003556069A patent/JP4393196B2/ja not_active Expired - Fee Related
- 2002-12-18 WO PCT/SE2002/002370 patent/WO2003055492A1/en not_active Ceased
- 2002-12-18 AT AT02793675T patent/ATE411801T1/de not_active IP Right Cessation
- 2002-12-18 AU AU2002359161A patent/AU2002359161A1/en not_active Abandoned
- 2002-12-18 EP EP02793675A patent/EP1458394B1/de not_active Expired - Lifetime
- 2002-12-18 DE DE60229554T patent/DE60229554D1/de not_active Expired - Lifetime
- 2002-12-18 US US10/499,950 patent/US20050070559A1/en not_active Abandoned
- 2002-12-19 UY UY27592A patent/UY27592A1/es unknown
2008
- 2008-12-09 US US12/330,834 patent/US20090312322A1/en not_active Abandoned
2009
- 2009-08-28 JP JP2009197776A patent/JP2010013460A/ja active Pending

Also Published As

Publication number	Publication date
WO2003055492A1 (en)	2003-07-10
ES2314123T3 (es)	2009-03-16
UY27592A1 (es)	2003-07-31
EP1458394B1 (de)	2008-10-22
JP2005516960A (ja)	2005-06-09
DE60229554D1 (de)	2008-12-04
AR037881A1 (es)	2004-12-09
US20090312322A1 (en)	2009-12-17
US20050070559A1 (en)	2005-03-31
AU2002359161A1 (en)	2003-07-15
JP4393196B2 (ja)	2010-01-06
TW200301123A (en)	2003-07-01
EP1458394A1 (de)	2004-09-22
JP2010013460A (ja)	2010-01-21

Legal Events

Date	Code	Title	Description
2009-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE411801T1 (de)	2008-11-15	Verwendung von oxindol-derivaten bei der behandlung von demenzbedingten krankheiten, alzheimer-krankheit und erkrankungen im zusammenhang mit glykogen-synthase-kinase-3
ATE345792T1 (de)	2006-12-15	Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
DE60233265D1 (de)	2009-09-17	5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
IS8135A (is)	2005-11-21	Þríhringtengdar indólafleiður og notkun þeirra til að meðhöndla Alzheimers-sjúkdóm
ATE448206T1 (de)	2009-11-15	Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen
NO2015018I1 (no)	2015-08-03	Safinamid for anvendelse i kombinasjon med levodopa/DPI samt eventuelt med andre PD medisinske produkter for behandling av Parkinsons sykdom
ATE286028T1 (de)	2005-01-15	Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60222671D1 (de)	2007-11-08	Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
ATE424837T1 (de)	2009-03-15	Verwendung von lanthan bei der behandlung von knochenerkrankungen
ATE232865T1 (de)	2003-03-15	1,4-diazabicyclo(3.2.2)nonan-4-carboxylat und carboxamidderivate, ihre herstellung und therapeutische verwendung
NO20053855L (no)	2005-11-21	1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
DE60318839D1 (de)	2008-03-13	2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE60325693D1 (de)	2009-02-26	Inaktivierung des west nile virus und plasmodium falciparum durch die verwendung von alloxazin-derivaten von photosensitizers
NO20043370L (no)	2004-09-28	N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
ATE269078T1 (de)	2004-07-15	Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
AU2003260744A1 (en)	2004-03-19	1, 4- substituted piperidine derivatives and use thereof as base-inhibitors in treatment of alzheimer's disease
IS6967A (is)	2003-09-24	Ný cýanó-tengd díhýdrópýrimídín efnasambönd og notkun þeirra við meðhöndlun sjúkdóma
Lightwood	2003	The economics of smoking and cardiovascular disease
ATE418552T1 (de)	2009-01-15	Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
NO20052699D0 (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
NO20040659L (no)	2004-02-13	Isoksazolopyridinoner og andvendelse derav ved behandling av Parkinsons sykdom
ITMI20010957A0 (it)	2001-05-10	Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche
ATE395919T1 (de)	2008-06-15	Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen
NO20043029L (no)	2004-10-11	Karboksamidinderivater og deres anvendelse ved behandling av vaskulaere sykdommer
NO20053341D0 (no)	2005-07-08	Hindring og behandling av Alzheimers sykdom.